Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 5/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14001877 | 1.00 | SAT1 (0.54) | SAT1CYP2C19CYP1A2MEN1GLA | |
| SCHEMBL15884023 | 1.00 | SAT1 (0.54) | SAT1CYP2C19CYP1A2MEN1GLA | |
| SCHEMBL12951342 | 1.00 | SAT1 (0.54) | SAT1CYP2C19CYP1A2MEN1GLA | |
| SCHEMBL12085585 | 1.00 | SAT1 (0.54) | SAT1CYP2C19CYP1A2MEN1GLA | |
| SCHEMBL14001872 | 0.98 | SAT1 (0.57) | SAT1CYP2C19CYP1A2MEN1GLA | |
| SCHEMBL14001876 | 0.98 | SAT1 (0.57) | SAT1CYP2C19CYP1A2MEN1GLA | |
| SCHEMBL15884118 | 0.95 | SAT1 (0.59) | SAT1CYP2C19CYP1A2MEN1GLA | |
| SCHEMBL18721523 | 0.95 | SAT1 (0.59) | SAT1CYP2C19CYP1A2MEN1GLA | |
| SCHEMBL10004983 | 0.95 | SAT1 (0.59) | SAT1CYP2C19CYP1A2MEN1GLA | |
| SCHEMBL12085581 | 0.95 | SAT1 (0.59) | SAT1CYP2C19CYP1A2MEN1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3228310-B1 | METHYLGLYOXAL BIS(GUANYL-HYDRAZONE) FOR REGULATING OSTEOPONTIN IN A SUBJECT | PATHOLOGICA LLC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20190224144-A1 | METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING | PATHOLOGICA LLC | 2019-07-25 | — | — | US | disclosed |
| US-20190224144-A1 | METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING | PATHOLOGICA LLC | 2019-07-25 | — | — | US | disclosed |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-10292950-B2 | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing | PATHOLOGICA LLC (US) | 2019-05-21 | — | — | US | disclosed |
| US-10292950-B2 | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing | PATHOLOGICA LLC (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180369170-A1 | METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING | PATHOLOGICA LLC | 2018-12-27 | — | — | US | disclosed |
| US-9867794-B2 | Regulation of osteopontin | PATHOLOGICA LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-20070287754-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PROGEN PHARMACEUTICALS, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070287754-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PROGEN PHARMACEUTICALS, INC. | 2007-12-13 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| WO-2007111993-A2 | POLYAMINE ANALOGS AS THERAPEUTIC AGENTS FOR SKIN DISEASES | CELLGATE, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20070232677-A1 | Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds | CELLGATE, INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232677-A1 | Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds | CELLGATE, INC. | 2007-10-04 | — | — | US | disclosed |
| US-7235695-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | SLIL BIOMEDICAL CORPORATION | 2007-06-26 | — | — | US | disclosed |
| US-7235695-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | SLIL BIOMEDICAL CORPORATION | 2007-06-26 | — | — | US | disclosed |
| WO-2007040535-A1 | USE OF POLYAMINE ANALOGS FOR TREATMENT AND PREVENTION OF INTESTINAL POLYPS | CELLGATE, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232677-A1 | Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds | SRM, SMS, PCNA | SAT1 38/4885CYP2C19 4775/4885CYP1A2 4812/4885 |
| US-20180369170-A1 | METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING | OPRK1, PTGES3, PTGES | SAT1 4651/4885CYP2C19 281/4885CYP1A2 505/4885 |
| US-20190224144-A1 | METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING | OPRK1, PTGES3, PTGES | SAT1 4651/4885CYP2C19 281/4885CYP1A2 505/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | SAT1 1880/4885CYP2C19 4252/4885CYP1A2 3593/4885 |
| US-20070287754-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PAICS, DHPS, DHFR | SAT1 47/4885CYP2C19 3900/4885CYP1A2 3677/4885 |
| US-10292950-B2 | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing | OPRK1, PTGES3, PTGES | SAT1 4651/4885CYP2C19 281/4885CYP1A2 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.